Biomea Fusion announced the FDA has cleared Biomea’s IND application for BMF-219 in type 2 diabetes to support the expansion of the COVALENT-111 study to sites in the U.S. Biomea management will host a conference call on Thursday, December 15 at 4PM EST to provide an overview of the COVALENT-111 study, as well as further details on the role of menin in diabetes and BMF-219’s potentially disease-modifying impact on beta cell health.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BMEA:
- Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes
- Biomea Fusion presents preclinical data on BMF-500 at ASH meeting
- Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date
- Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference
- Biomea Fusion reports Q3 EPS (78c), consensus (65c)
